Emerging therapeutic options for acute migraine: focus on the potential of lasmiditan

Paul B RizzoliDepartment of Neurology, Brigham and Women’s Faulkner Hospital, John R. Graham Headache Center, Boston, MA, USACorrespondence[email protected]

Pages 547-552 | Published online: 31 Mar 2014

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

SmithermanTABurchRSheikhHLoderEThe prevalence, impact, and treatment of migraine and severe headaches in the United States: a review of statistics from national surveillance studiesHeadache201353342743623470015
PubMed Web of Science ®Google Scholar
MurrayCJVosTLozanoRDisability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010Lancet201238098592197222323245608
PubMed Web of Science ®Google Scholar
MagisDSchoenenJTreatment of migraine: update on new therapiesCurr Opin Neurol201124320321021464715
PubMed Web of Science ®Google Scholar
StovnerLJTronvikEHagenKNew drugs for migraineJ Headache Pain200910639540619795182
PubMed Web of Science ®Google Scholar
RamadanNMSkljarevskiVPhebusLAJohnsonKW5-HT1F receptor agonists in acute migraine treatment: a hypothesisCephalalgia200323877678514510923
PubMed Web of Science ®Google Scholar
NelsonDLPhebusLAJohnsonKWPreclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditanCephalalgia201030101159116920855361
PubMed Web of Science ®Google Scholar
OlesenJ5-Hydroxyptryptamine 1F (5-HT1F) receptor agonism. A possible new treatment principle for acute migraine attacksCephalalgia201030101157115820855360
PubMed Web of Science ®Google Scholar
RamadanNMThe link between glutamate and migraineCNS Spectr20038644644912858134
PubMed Web of Science ®Google Scholar
GoldsteinDJRoonKIOffenWWSelective seratonin 1F (5-HT[1F]) receptor agonist LY334370 for acute migraine: a randomised controlled trialLancet200135892891230123411675061
PubMed Web of Science ®Google Scholar
GeraudGKeywoodCSenardJMMigraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptansHeadache200343437638812656709
PubMed Web of Science ®Google Scholar
MaggioniFPiniLAZanchinGPreclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. A commentCephalalgia2011319106121511951
PubMed Web of Science ®Google Scholar
FerrariMDFarkkilaMReuterUAcute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan – a randomised proof-of-concept trialCephalalgia201030101170117820855362
PubMed Web of Science ®Google Scholar
FarkkilaMDienerHCGeraudGEfficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a Phase II randomised, placebo-controlled, parallel-group, dose-ranging studyLancet Neurol201211540541322459549
PubMed Web of Science ®Google Scholar
FerrariMDGoadsbyPJRoonKILiptonRBTriptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trialsCephalalgia200222863365812383060
PubMed Web of Science ®Google Scholar
LoderEGoldsteinRBiondiDPlacebo effects in oral triptan trials: the scientific and ethical rationale for continued use of placebo controlsCephalalgia200525212413115658949
PubMed Web of Science ®Google Scholar
Tfelt-HansenPCOlesenJThe 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled Phase II trialsJ Headache Pain201213427127522430431
PubMed Web of Science ®Google Scholar
OlesenJAshinaMEmerging migraine treatments and drug targetsTrends Pharmacol Sci201132635235921459461
PubMed Web of Science ®Google Scholar
CharlesADefining and refining 5-HT receptor targets for migraineLancet Neurol201211538338422459548
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Emerging therapeutic options for acute migraine: focus on the potential of lasmiditan

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Emerging therapeutic options for acute migraine: focus on the potential of lasmiditan

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date